UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): December 6, 2021
STRATA SKIN SCIENCES, INC.
(Exact Name of Registrant Specified in Charter)
Delaware
| 000-51481
| 13-3986004
|
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
| 5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania | | 19044
|
| (Address of Principal Executive Offices) | | (Zip Code) |
Registrant's telephone number, including area code: 215-619-3200
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading
Symbol(s) | Name of each exchange on which registered |
Common Stock, $0.001 par value per share
| SSKN
| The NASDAQ Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On December 6, 2021, LuAnn Via submitted her letter of resignation, effective December 31, 2021, from her position as a Board member, Vice Chairperson, and Chair of the Board's Audit Committee of Strata Skin Sciences, Inc. (the “Company”). This resignation is not a result of any disagreement or dispute related to Strata’s operations, accounting policies, or practices. On the same date, Douglas Strang, a member of the Company's Board and a member of the Audit Committee, agreed to serve as Chair of the Audit Committee effective upon Ms. Via’s resignation.
| Item 7.01. | Regulation FD Disclosure. |
On December 9, 2021, the Company issued a press release announcing the appointment of Douglas Strang as Chair of the Audit Committee and the resignation of LuAnn Via from her positions on the Board of the Company. The full text of such press release is furnished as Exhibit 99.1 to this report.
The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
| Item 9.01. | Financial Statements and Exhibits. |
| 99.1 | Press release, dated December 9, 2021, of Strata Skin Sciences, Inc. |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | STRATA SKIN SCIENCES, INC. |
| | | |
| Date: December 9, 2021 | By: | /s/ Christopher Lesovitz |
| | | Christopher Lesovitz |
| | | Chief Financial Officer |
